Qualitative Research on IgPro20 Pre‑Filled Syringe Use Among US Patients with Primary Immunodeficiencies

Batyrkhan Kuatov,1 Gemma Al-Jassar,2 Katja Rudell,2 Tommi Tervonen,3 Anita Burrell,4 Shicheng Weng,5 Julia Braverman61HEOR, Global Market Access, CSL Behring, Bern, Switzerland; 2Kielo Research, York, UK; 3Kielo Research, Zug, Switzerland; 4Anita Burrell Consulting LLC, Flemington, NJ, USA; 5Medical Affairs and HTA Statistics, CSL Behring, Waltham, MA, USA; 6Patient Centered Science, CSL Behring, Waltham, MA, USACorrespondence: Julia Braverman, Patient Centered Science, CSL Behring, 225 Wyman Street, Waltham, 02451, USA, Email [email protected]: Primary immunodeficiency (PID) patients can receive subcutaneous immunoglobulin (SCIG) therapy using vials or pre-filled syringes (PFS). This research explored patient experience in the United States (US) with both presentation forms related to adherence, satisfaction, convenience, and impacts to quality-of-life.Patients and Methods: A cross-sectional, qualitative interview study of 24 US PID patients currently administering IgPro20 PFS and who have prior experience in using vials.Results: Patient’s mean age was 54 years (median = 51, range 23– 79), 17% were male and 83% were female, and mean time since diagnosis was 16 years (median = 12, range 3– 47). Most patients (83%) reported being more satisfied with IgPro20 PFS than vials and found them more convenient (75%). Reasons included readiness for use, shorter preparation time, and no residual product. More patients reported never missing or skipping a dose with IgPro20 PFS (67%) compared with vials (29%), citing reasons such as ease of preparation and IgPro20 PFS being more travel-friendly. Moreover, 50% of patients reported positive emotional impact of changing from vials to IgPro20 PFS, related to being less anxious. As expected, there was neutrality for overall health, and daily, work-related, and social activities.Conclusion: Participants experienced in both SCIG presentation forms were more satisfied, reported improved convenience, and were more adherent with IgPro20 PFS compared with vials. The positive benefits expressed included reduced residual product and emotional impacts driven by greater assurance of taking their full dose. Further research is required to more fully illustrate the perceptions of patients and how this potentially impacts their quality-of-life.Keywords: IgPro20, immunoglobulin G, IgG, intravenous immunoglobulin, IVIG, pre-filled syringe, PFS, primary immunodeficiency disease, PID, subcutaneous immunoglobulin, SCIG